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Abstract 
 
Background:  
Polycystic ovarian syndrome (PCOS) is the commonest reproductive disorder in women and is closely 
associated with the development of metabolic syndrome (MetS). The objective of this systematic review 
and meta-analysis was to describe the risk of MetS in adolescent with PCOS to help diagnosing and 
preventing of morbidity and mortality later in life. 
 
Methods: 
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Pubmed, Medline, EMBASE, CINAHL and other sources were searched for metabolic syndrome in 
adolescents with polycystic ovarian syndrome using PRISMA guidelines (Moher et al., 2009). All type of 
study design of women aged 10-20 reported association of PCOS with metabolic syndrome was included in 
this study.  Meta-analysis was conducted for MetS and its individual component using bias adjusted quality 
effect model and we compare the results from quality effects with random effects and IVhet model. Data 
were presented as prevalence, odds ratio (95% confidence interval and mean difference (95% confidence 
interval). 
 
Results: 
This systematic review included 9 studies while the meta-analysis included 7 studies. Meta-analysis 
showed that the odds of being experiencing MetS in PCOS groups was 2.69 (1.29, 5.60) times than girls 
without PCOS. The mean difference between girls with PCOS and without PCOS for systolic blood pressure 
was 5.00 (1.28, 8.72), diastolic blood pressure was 3.50 (0.48, 6.56), triglycerides level was 4.20 (-3.99, 
12.45), glucose level was 1.30 (-0.46, 3.05), HDL level was -1.40 (-4.85, 2.00).  
 
Conclusion: 
This systematic review and meta-analysis support the hypothesis that the risk of MetS is much greater in 
adolescents with PCOS compared to the normal population. It is important to screen PCOS in early age to 
prevent MetS and its complications which lead to morbidity and mortality later in life. 
 
Abbreviations 
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BP   Blood Pressure  
CINAHL  Cumulative Index to Nursing and Allied Health Literature 
DBP   Diastolic Blood Pressure 
EMBASE  Excerpta Medical Database 
ESHRE   European Society of Human Reproduction and Embryology 
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HDL   High Density Lipid 
IDF   International Diabetes Federation 
LDL   Low Density Lipid 
MeSh   Medical Subject Heading 
MetS   Metabolic Syndrome 
NCEP ATP III National Cholesterol Education Program Expert Panel on Detection, Evaluation and 
Treatment of High Blood Cholesterol in Adults 
NIH   National Institute of Health 
PCOS    Polycystic Ovarian Syndrome 
PRISMA  Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
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Polycystic ovary syndrome (PCOS) is the most common reproductive disorder in women characterized by 
hirsutism, infertility, menstrual irregularities, obesity, and polycystic ovaries (Stepto et al. 2013). The 
aetiology is unknown but PCOS is associated with dysfunctional uterine bleeding, endometrial carcinoma, 
diabetes, mood disorder, dyslipidemia, infertility and hypertension (Goodarzi et al. 2011; Stepto et al., 
2013; March et al., 2010). These women are at high risk of cardiovascular morbidity and mortality in later 
life (Goodarzi et al. 2011). It is estimated to affect up to 10% of reproductive-aged women worldwide 
according to 1990 National Institute of Health (NIH) criteria and even more using the Rotterdam criteria 
(Blank et al. 2008; Goodarzi et al., 2011). In Australia, the prevalence of PCOS is estimated at about 6-7% of 
reproductive women especially in the Aboriginal population (Dabadghao et al., 2007). PCOS usually occur 
during puberty (Cirik & Dilbaz 2014).The etiology is still unknown but recent studies suggest that the 
principal underlying disorder is one of insulin resistance with hyperinsulinaemia stimulating excess 
androgen production. This insulin hormonal dysregulation associated with PCOS begins in adolescence 
(Blank et al. 2008). Genetics and environmental factors are also proposed to be causes of PCOS. Women 
are at risk if they have a genetic predisposition, although the onset of symptoms can be triggered by 
environmental factors, particularly obesity (Boyle & Teede 2012). 
 
During the last decade, the prevalence of metabolic syndrome (MetS) has increased in men and women 
especially in young people (Cirik & Dilbaz 2014). Metabolic features start in adolescence and increase with 
age (Cirik & Dilbaz, 2014). As PCOS and the metabolic syndrome share insulin resistance as an important 
element in their pathophysiology, there is much overlap between the two clinical arenas (Sartor & Dickey 
2005). It has been suggested that PCOS may be the female-specific manifestation of the metabolic 
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syndrome (Sartor & Dickey 2005). However, the evidence of the association between PCOS and MetS 
among young women in less studied. 
 
A systematic review of the association between MetS and PCOS has been performed (Kandaraki, 
Christakou & Diamanti-Kandarakis 2009). This study reviewed the prevalence of MetS in women with PCOS 
and found the women appeared to be more susceptible to developing MetS (Kandaraki, Christakou & 
Diamanti-Kandarakis 2009). However, the outcomes were generally for women in the reproductive age 
group. The onset of PCOS occurs during puberty and no systematic review and meta-analysis to relate 
PCOS with the development of MetS in adolescents. Findings of this study will have implication to detect 
MetS in early stage of life to prevent future morbidity and mortality. 
 
Methods 
Search Strategy 
We conducted a Pubmed, Medline, EMBASE, CINAHL and other sources search of Metabolic Syndrome in 
adolescents with Polycystic Ovarian Syndrome using PRISMA guidelines (Moher et al. 2009). All type of 
study design of women aged 10-20 years reported association of PCOS with metabolic syndrome was 
included in this study.  Adolescent girls with conditions similar to PCOS such as hyperprolactinaemia, 
cushing’s syndrome, hyperthyroidism, hypothyroidism and congenital adrenal hyperplasia were excluded 
from the review.  
 
Defining PCOS 
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There are two available criteria for PCOS diagnosis; NIH (National Institute of Health) and 
Rotterdam/European Society of Human Reproduction and Embryology (ESHRE) criteria. The 
Rotterdam/ESHRE consensus is the most widely used in Europe, Australia and Asia (Boyle & Teede 2012) 
because Rotterdam/ESHRE guidelines allows early diagnosis of PCOS. The NIH generally describes women 
with a more severe form of PCOS which require both hyperandrogenism and anovulation while the 
Rotterdam/ESHRE only requires two of three criteria; hyperandrogenism, anovulation or polycystic ovaries 
(Carmina 2004). For studies to be included in this review PCOS was defined according to the NIH or 
Rotterdam/ESHRE criteria (Table 1). Participants were not excluded based on ethnicity. 
 
Metabolic Syndrome 
 
There are various definition of Metabolic Syndrome in adolescents such as those reported by the The 
International Diabetes Federation (IDF), WHO (World Health Organization), National Cholesterol Education 
Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (NCEP 
ATP III), Guidelines of Prevention of Atherosclerosis in Childhood and Adolescence (IDPAIA) and those by 
various authors; Cook et al, de Ferranti et al, Cruz and Goran, Weiss et al and Ford Diabetes Care (Silveira 
et al. 2013). We included studies that defined Metabolic Syndrome in adolescents and young adults (aged 
10-20 years) according to Cook (Cook et al. 2003), de Ferranti (de Ferranti et al. 2004), NCEP ATP lll (Panel 
2002) and IDF adolescent criteria (Alberti et al. 2007). In this review, most of the studies used the IDF 
definition which is the latest and is standardized for children and adolescents according to age group 
(Silveira et al. 2013). Results were categorized into metabolic syndrome’s symptoms; central obesity, high 
blood pressure, high density lipid (HDL) and triglyceride level, and glucose level. 
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Data extraction 
 
Data collected for the study comprised general study characteristics ( age, BMI, study design, number of 
girls with and without PCOS, recruitment source, sampling method), definition of PCOS (NIH or 
Rotterdam/ESHRE), medical history, medication use, definition of Metabolic Syndrome ( de Ferranti, Cook, 
IDF paediatric and NCEP ATP III), measurement of waist circumference, lipid level, glucose level and blood 
pressure. One reviewer extracted the data from all articles and another reviewer checked for mis-matches. 
Discrepancies were resolved by consensus. 
 
Methodology Assessment 
The quality of the included studies was assessed using The Cochrane Collaboration Tool since it is the most 
commonly used for assessing risk of bias for systematic reviews (Higgins et al. 2011). This tool assessed the 
selection of PCOS and control groups, the comparability between them and the quality of outcome 
measures. This tool uses a ‘star system’; the highest quality studies were awarded up to a total 9 stars 
(appendix 2). For meta-analysis, we used bias-adjusted quality effects model to allows the good quality 
studies to give more weight towards the overall effect size (Doi et al. 2011).  
 
Results 
Characteristics of included studies 
The search yielded 266 studies (Figure 1). After assessments of title abstract and full-length articles, for 
final analysis, 9 studies were included (Table 3). All included studies were observational cross-sectional or 
case controlled studies except 3 studies; 2 medical records reviews and one longitudinal cohort (Fruzzetti 
et al. 2009, Bhattacharya 2008, Hart et al. 2011). PCOS diagnosis in five of the studies used the 
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Rotterdam/ESHRE criteria (Bhattacharya 2008, Panidis et al. 2013, Rossi et al. 2008, Aydin et al. 2014, 
Vrbikova et al. 2011), one study used the NIH criteria (Rahmanpour et al. 2012), three studies used NIH 
or/and Rotterdam criteria (Huang et al. 2010, Fruzzetti et al. 2009, Hart et al. 2011).  
Methodology quality 
 
All studies were found to have low risk of performance, attrition and reporting bias while only three 
studies were at high risk of selection bias (Bhattacharya 2008, Hart et al. 2011, Aydin et al. 2014). All 
studies provided adequate criteria for the diagnosis of PCOS and MetS. All studies reported complete 
outcomes and how the outcomes were measured (Table 4). Six studies were cross-sectional or case-
control studies (Aydin et al. 2014, Panidis et al. 2013, Rossi et al. 2008, Vrbikova et al. 2011, Huang et al. 
2010, Rahmanpour et al. 2012) , one is longitudinal cohort study (Hart et al. 2011) and two studies were 
chart review (Bhattacharya 2008, Fruzzetti et al. 2009). Six studies excluded endocrinal disorders, two 
studies excluded alcohol, smoking and drug intake, one study excluded cardiovascular diseases, one study 
excluded pregnancy and two other studies did not stated their exclusion criteria. 
 
 
Systematic review 
 
Blood Pressure Level 
 
Only one study reported a greater prevalence of high systolic and diastolic blood pressure in girls with 
PCOS (Aydin et al. 2014). Two studies found that only systolic blood pressure (SBP) was significantly higher 
in girls with PCOS compared with control groups (Fruzzetti et al. 2009, Panidis et al. 2013). while 
Rahmanpour et al showed diastolic blood pressure (DBP) was significantly different between PCOS and 
control group (Rahmanpour et al. 2012). Four studies reported there were no significant differences in SBP 
and DBP between the groups (Hart et al. 2011, Huang et al. 2010, Rossi et al. 2008, Vrbikova et al. 2011). 
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(Bhattacharya 2008) found that 47.1% of girls with PCOS had elevated SBP while only 5.9% of them had 
elevated DBP. 
 
 
Lipids level 
 
Three studies showed adolescents with PCOS displayed significantly greater in triglycerides levels 
compared to control groups (Rahmanpour et al. 2012, Aydin et al. 2014, Fruzzetti et al. 2009). Two studies 
reported that girls with PCOS had decreased HDL level compared to control groups (Fruzzetti et al., 2009, 
Vrbikova et al. 2011) and (Bhattacharya 2008) reported 35% of PCOS girls has low HDL level. There were 
no significant differences in HDL levels and triglycerides levels reported in four studies (Rossi et al. 2008, 
Hart et al. 2011, Huang et al. 2010, Panidis et al. 2013).  
 
Blood Sugar Level 
Only one study found that fasting blood glucose was significantly higher in PCOS girls compared to the 
control group (Fruzzetti et al. 2009). Another seven studies reported there were no significant differences 
between PCOS girls and control groups in fasting glucose or glucose level (Aydin et al. 2014, Huang et al. 
2010, Vrbikova et al. 2011, Rahmanpour et al. 2012, Rossi et al. 2008, Panidis et al. 2013, Hart et al. 2011).  
(Bhattacharya 2008), higher plasma glucose was found in 11.8% in PCOS girls. 
 
 
Central Obesity 
 
Three studies showed adolescents with PCOS displayed significantly greater waist circumference compared 
to control groups (Rahmanpour et al. 2012, Panidis et al. 2013, Huang et al. 2010) while three studies 
reported no significant difference between PCOS and control groups in waist circumference (Rossi et al. 
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2008, Aydin et al. 2014, Vrbikova et al. 2011). Waist circumference was not reported by (Bhattacharya 
2008). 
 
Prevalence of Metabolic Syndrome 
 
Prevalence of MetS in the included studies ranges from 4.9% to 43.6% in adolescent girls with PCOS. 
Adolescent girls with PCOS had a higher prevalence of metabolic syndrome compared to control groups in 
four studies (Aydin et al. 2014, Huang et al. 2010, Rahmanpour et al. 2012, Hart et al. 2011). Also, 
(Bhattacharya 2008) reported metabolic syndrome was found in 43.6% of adolescent girls with PCOS. 
However, three studies reported that PCOS did not add additional risk for metabolic syndrome (Rossi et al. 
2008, Vrbikova et al. 2011, Panidis et al. 2013).  
 
 
Meta-analysis 
For meta-analysis, we used the funnel plot to assess publication bias and bias adjusted quality effects 
model instead of random effects and Inverse Variance Heterogeneity (IVhet) model for the main result 
(Doi et al. 2015a). Bias-adjusted quality effects model is an updated model that allows study quality 
information to be incoperated into the analysis (Barendregt & SA, Doi et al. 2015a).   The mean differences 
between PCOS and control groups for systolic and diastolic pressure are 5.0 and 3.5 respectively (Figure 1 
& 2). The mean difference in triglycerides level also shows that PCOS groups are 4 times higher compared 
to control groups (Figure 5) and 5 times greater in waist circumference (Figure 7). In glucose and HDL 
levels, there is not much difference between these two groups (Figure 6). Meta-analysis showed that the 
odd of being experiencing MetS in PCOS groups is 2.69 (1.29, 5.60) times higher than girls without PCOS 
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(Figure 8). Results are not substantially different using random effects model (2.73(1.37, 5.45)) and IVhet 
model (2.39 (1.18, 4.84). 
 
 
Discussion 
This is the first systematic review and meta-analysis to assess the risk of metabolic syndrome in 
adolescents with PCOS. We found that adolescents with PCOS had 2.69 times higher risk for metabolic 
syndrome compared to healthy girls when the quality scores were considered. The clinical features of 
metabolic syndrome of both groups were also presented as weighted mean difference and showed PCOS 
girls had higher level of triglycerides, glucose, blood pressure and waist circumference while lower in HDL 
level compared to girls without PCOS. This findings support the hypothesis; adolescent girls with polycystic 
ovarian syndrome have an increased risk of metabolic syndrome. 
 
Four US studies have reported that 33.4% to 47.3% of obese women with PCOS fulfill the NCEP ATPIII 
criteria for metabolic syndrome (Glueck et al. 2003, Apridonidze et al. 2005, Ehrmann et al. 2006, Dokras 
et al. 2005). However these studies estimated the prevalence of metabolic syndrome in PCOS women in 
reproductive age without properly matched for age. European studies have reported that women with 
PCOS and a lower BMI have a lower risk of metabolic syndrome compared to US studies of US women 
(Carmina 2004, Vural et al. 2005, Vrbikova et al. 2011). One study reported PCOS and MS are mutually 
related (Kandaraki, Christakou & Diamanti-Kandarakis 2009). 
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PCOS appeared to be closely associated with MetS. Most of PCOS patients have features of MetS such as 
obesity, dyslipidemia, and insulin resistance that may lead to cardiovascular disease and stroke (Stepto et 
al. 2013). Studies have shown that the androgen excess in women with PCOS plays an important role in 
aggravation of central adiposity and insulin resistance (Kandaraki, Christakou & Diamanti-Kandarakis 
2009). It has been reported that androgen administration to obese women lead to deposition of visceral 
fat (Kandaraki, Christakou & Diamanti-Kandarakis 2009). Both PCOS and MetS also have an inter-related 
relation to insulin resistance and hypercholesterolemia (Stepto et al. 2013). Impaired glucose tolerance 
and increased cholesterol and triglycerides are important features in PCOS which are also features of MetS 
(Cirik & Dilbaz 2014). This paper has shown that features of MetS are common in girls with PCOS and it has 
shown that adolescent girls with PCOS are more susceptible of developing MetS compared to normal 
healthy girls. 
 
This study used a bias-adjusted quality effects model for meta-analysis. The strength in quality effects 
model is that it allows the good quality studies to give more weight towards the overall effect size (Doi et 
al. 2011). It helps to close the damaging gap which has opened up between methodology and statistics in 
the research (Doi & Thalib 2008). It also demonstrates that despite the subjectivity of quality assessment, 
the performance is superior to that achievable with random effects model (Doi et al. 2015, Doi et al. 2015). 
However, for the comparison purpose, we also used random-effects and IVhet models and found that the 
results are not substantially different. 
 
Most of the studies in this paper were comparative cross-sectional studies between PCOS girls with 
healthy girls (Aydin et al. 2014; Panidis et al. 2013; Vrbikova et al. 2011; Huang et al. 2010; Rossi et al. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
13 
 
2008; Rahmanpour et al. 2012). Cross-sectional studies were carried out to investigate the association 
between polycystic ovarian syndrome and metabolic syndrome. However, temporal bias is common in this 
study design; when the exposure and outcome data are collected at the same time. It gives no indication 
of the sequence of the events, of whether polycystic ovarian syndrome occurred before, during or after 
the occurrence of metabolic syndrome. Publication bias was assessed using the funnel plot for prevalence 
of metabolic syndrome and its components (figure 9-15). The asymmetry funnel plot in this meta-analysis 
suggested possible publication bias existed. It could not be excluded since it is related to language and 
citation biases during the selective inclusion of the studies.  
 
Accurate diagnosis of PCOS is one of the problems. In adolescents, abnormal menstruation, transient 
hyperandrogenemia and enlarged ovaries are common but not due to PCOS (Greydanus et al. 2009). This 
problem may overestimate the prevalence of the PCOS. Also, the studies use different criteria for the 
diagnosis of PCOS; Rotterdam/ESHRE and NIH. The use of the Rotterdam criteria (in Europe) alone may 
overestimate the incidence of PCOS. In this review, we only included girls with PCOS who had chronic 
anovulation, at least one year after menarche and hirsuitism which was defined by the Ferriman Gallway 
score as higher than eight. However, in young girls, menstrual cycles make take up to two years to regulate 
after menarche(Boyle & Teede 2012). Another limitation is ultrasound which does not reliably detect 
polycystic ovaries in adolescent girls because 70% of them may have enlarged ovaries on ultrasound (Boyle 
& Teede 2012).  
 
The diagnosis of MetS in this study was evaluated using four different criteria; Cook et al, de Ferranti, NCEP 
ATPIII and IDF for adolescents as there is no universal definition of MetS for adolescents (Cook et al. 2003; 
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de Ferranti et al. 2004; Panel 2002; Alberti et al. 2007). Adolescence recommendations should be updated 
to screen and identify girls at an early age which may be useful in the prevention of cardiovascular disease 
and type 2 diabetes mellitus later in life (Cruz & Goran 2004). Both Cook et al and de Ferranti et al 
suggested the importance of diagnosing MetS in adolescents. However, the cut-off point for HDL in Cook 
et al is 40mg/dL and in de Ferranti et al is 50mg/dL and the cut-off point for waist circumference is 90th 
percentile and 75th percentile respectively. In (Bhattacharya 2008), IDF criteria was used for MetS 
diagnosis but the cut-off point for HDL of 50mg/dL which is similar to the cut-off point for adults.  
 
Another limitation of this paper is not all studies used the same BMI values for determining those that 
were considered abnormal.  (Aydin et al. 2014) only included girls with BMI less than 25kg/m2 while Rossi 
et al (2008) only included girls with BMI >25kg/m2. In Rahmanpour et al and Panidis et al, obesity was 
found to be an important factor for metabolic abnormalities (Rahmanpour et al. 2012; Panidis et al. 2013). 
Differences in accepted abnormal BMI levels could definitely account for variations in the prevalence of 
MetS. Obesity and insulin resistance play an important role in gonadotrophic dysfunction leading to excess 
androgen synthesis and related clinical features such as hirsutism and menstrual abnormalities (Anderson 
et al. 2014). We found that obesity could worsen metabolic disorders in girls with PCOS. 
 
Lastly, we conclude that these findings can help in early detection of metabolic syndrome, considering 
metabolic syndrome plays an important role in cardiovascular diseases and stroke (Boyle & Teede 2012). 
This systematic review and meta-analysis highlights the need for greater awareness among adolescent girls 
since onset of PCOS starts during puberty (Connor 2012). This disorder is a significant public health 
concern in society which therefore indicates a need to identify the proportion of women affected in all age 
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(March et al. 2010). It cannot be prevented but lifestyle modification in early age such as weight loss, diet 
and exercise is highly recommended as an important strategy to treat PCOS and its complications. Other 
treatment for PCOS depends on the symptoms; hormones supplements for irregular menses, anti-
androgen for hirsutism (Connor 2012). 
 
Conclusion 
Overall, adolescent girls diagnosed with PCOS appear to be more susceptible to develop metabolic 
syndrome. Eventhough this review has several limitations, many research studies have shown that PCOS 
and Metabolic Syndrome are highly related and seem to have major clinical implications such as 
cardiovascular disease later on (Apridonidze et al. 2005). To minimize the morbidity and mortality from the 
related diseases, Metabolic Syndrome and PCOS should be diagnosed and treated in adolescence when 
symptoms first appear. Further study and research should be conducted to reflect the actual cause and 
management of PCOS and metabolic syndrome in order to decrease the morbidity and mortality 
worldwide. 
 
Conflict of Interest 
Polycystic ovarian syndrome (PCOS) is the commonest reproductive disorder in women and is closely 
associated with the development of metabolic syndrome (MetS). The objective of this systematic review 
and meta-analysis was to describe the risk of MetS in adolescent with PCOS to help diagnosing and 
preventing of morbidity and mortality later in life. 
 
Acknowledgments 
AC
CE
PT
ED
 M
AN
US
CR
IPT
16 
 
I would like to express my sincere gratitude to my supervisors, Associate Professor Abdullah Mamun and 
Professor Maxine Whittaker for continues support and guidance. Also, I sincerely appreciate the editing of 
this review by Vivienne Chavez and Scott Macintyre who has helped me a lot in general. Last but not least, 
I would like to thank my family; my parents and my brothers for supporting me endlessly throughout my 
life. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
17 
 
References: 
2012. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod, 27, 14-24. 
ALBERTI, G., ZIMMET, P., KAUFMAN, F., TAJIMA, N., SILINK, M., ARSLANIAN, S., WONG, G., 
BENNETT, P., SHAW, J. & CAPRIO, S. 2007. The IDF consensus definition of the metabolic 
syndrome in children and adolescents. International Diabetes Federation. 
ANDERSON, A. D., SOLORZANO, C. M. B. & MCCARTNEY, C. R. Childhood obesity and its impact 
on the development of adolescent PCOS.  Seminars in reproductive medicine, 2014. NIH Public 
Access, 202. 
APRIDONIDZE, T., ESSAH, P. A., IUORNO, M. J. & NESTLER, J. E. 2005. Prevalence and 
characteristics of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of 
Clinical Endocrinology & Metabolism, 90, 1929-1935. 
AYDIN, Y., HASSA, H., BURKANKULU, D., ARSLANTAS, D., SAYINER, D. & OZERDOGAN, N. 
2014. What is the Risk of Metabolic Syndrome in Adolescents with Normal BMI who have 
Polycystic Ovary Syndrome? J Pediatr Adolesc Gynecol. 
BARENDREGT, J. & SA, D. Epigear (2012) MetaXL. 2012. 
BHATTACHARYA, S. M. 2008. Metabolic syndrome in females with polycystic ovary syndrome and 
International Diabetes Federation criteria. Journal of Obstetrics and Gynaecology Research, 34, 62-
66. 
BLANK, S. K., HELM, K. D., MCCARTNEY, C. R. & MARSHALL, J. C. 2008. Polycystic ovary 
syndrome in adolescence. Ann N Y Acad Sci, 1135, 76-84. 
BOYLE, J. & TEEDE, H. J. 2012. Polycystic ovary syndrome - an update. Aust Fam Physician, 41, 752-6. 
CARMINA, E. 2004a. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM 
guidelines. Minerva ginecologica, 56, 1-6. 
CARMINA, E. 2004b. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM 
guidelines. Minerva Ginecol, 56, 1-6. 
CIRIK, D. A. & DILBAZ, B. 2014. What do we know about metabolic syndrome in adolescents with 
PCOS? J Turk Ger Gynecol Assoc, 15, 49-55. 
CONNOR, E. L. 2012. Adolescent polycystic ovary syndrome. Adolesc Med State Art Rev, 23, 164-77, xii. 
COOK, S., WEITZMAN, M., AUINGER, P., NGUYEN, M. & DIETZ, W. H. 2003. Prevalence of a 
metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition 
Examination Survey, 1988-1994. Archives of pediatrics & adolescent medicine, 157, 821-827. 
CRUZ, M. L. & GORAN, M. I. 2004. The metabolic syndrome in children and adolescents. Curr Diab Rep, 
4, 53-62. 
DABADGHAO, P., ROBERTS, B. J., WANG, J., DAVIES, M. J. & NORMAN, R. J. 2007. Glucose 
tolerance abnormalities in Australian women with polycystic ovary syndrome. Med J Aust, 187, 328-
31. 
DE FERRANTI, S. D., GAUVREAU, K., LUDWIG, D. S., NEUFELD, E. J., NEWBURGER, J. W. & 
RIFAI, N. 2004. Prevalence of the metabolic syndrome in American adolescents findings from the 
Third National Health and Nutrition Examination Survey. Circulation, 110, 2494-2497. 
DOI, S. A., BARENDREGT, J. J., KHAN, S., THALIB, L. & WILLIAMS, G. M. 2015a. Advances in the 
meta-analysis of heterogeneous clinical trials II: The quality effects model. Contemp Clin Trials, 45, 
123-9. 
DOI, S. A., BARENDREGT, J. J., KHAN, S., THALIB, L. & WILLIAMS, G. M. 2015b. Simulation 
Comparison of the Quality Effects and Random Effects Methods of Meta-analysis. Epidemiology, 
26, e42-4. 
AC
CE
PT
D M
AN
US
CR
IPT
18 
 
DOI, S. A., BARENDREGT, J. J. & MOZURKEWICH, E. L. 2011. Meta-analysis of heterogeneous 
clinical trials: an empirical example. Contemp Clin Trials, 32, 288-98. 
DOI, S. A. & THALIB, L. 2008. A quality-effects model for meta-analysis. Epidemiology, 19, 94-100. 
DOKRAS, A., BOCHNER, M., HOLLINRAKE, E., MARKHAM, S., VANVOORHIS, B. & JAGASIA, D. 
H. 2005. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet 
Gynecol, 106, 131-7. 
EHRMANN, D. A., LILJENQUIST, D. R., KASZA, K., AZZIZ, R., LEGRO, R. S. & GHAZZI, M. N. 
2006. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary 
syndrome. J Clin Endocrinol Metab, 91, 48-53. 
FRANKS, S. 2006. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. The 
Journal of Clinical Endocrinology & Metabolism, 91, 786-789. 
FRUZZETTI, F., PERINI, D., LAZZARINI, V., PARRINI, D. & GENAZZANI, A. R. 2009. 
Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in 
adolescents with the polycystic ovary syndrome. Gynecological Endocrinology, 25, 335-343. 
GLUECK, C. J., PAPANNA, R., WANG, P., GOLDENBERG, N. & SIEVE-SMITH, L. 2003. Incidence 
and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian 
syndrome. Metabolism, 52, 908-15. 
GOODARZI, M. O., DUMESIC, D. A., CHAZENBALK, G. & AZZIZ, R. 2011. Polycystic ovary 
syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol, 7, 219-31. 
GREYDANUS, D. E., OMAR, H. A., TSITSIKA, A. K. & PATEL, D. R. 2009. Menstrual disorders in 
adolescent females: current concepts. Disease-a-month, 55, 45-113. 
HART, R., DOHERTY, D. A., MORI, T., HUANG, R. C., NORMAN, R. J., FRANKS, S., SLOBODA, D., 
BEILIN, L. & HICKEY, M. 2011. Extent of metabolic risk in adolescent girls with features of 
polycystic ovary syndrome. Fertil Steril, 95, 2347-53, 2353.e1. 
HIGGINS, J. P., ALTMAN, D. G., GØTZSCHE, P. C., JÜNI, P., MOHER, D., OXMAN, A. D., 
SAVOVIĆ, J., SCHULZ, K. F., WEEKS, L. & STERNE, J. A. 2011. The Cochrane Collaboration’s 
tool for assessing risk of bias in randomised trials. Bmj, 343, d5928. 
HUANG, J., NI, R., CHEN, X., HUANG, L., MO, Y. & YANG, D. 2010. Metabolic abnormalities in 
adolescents with polycystic ovary syndrome in south China. Reproductive Biology and 
Endocrinology, 8, 142. 
KANDARAKI, E., CHRISTAKOU, C. & DIAMANTI-KANDARAKIS, E. 2009. Metabolic syndrome and 
polycystic ovary syndrome... and vice versa. Arquivos Brasileiros de Endocrinologia & 
Metabologia, 53, 227-237. 
MARCH, W. A., MOORE, V. M., WILLSON, K. J., PHILLIPS, D. I., NORMAN, R. J. & DAVIES, M. J. 
2010. The prevalence of polycystic ovary syndrome in a community sample assessed under 
contrasting diagnostic criteria. Hum Reprod, 25, 544-51. 
MOHER, D., LIBERATI, A., TETZLAFF, J. & ALTMAN, D. G. 2009. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine, 151, 
264-269. 
PANEL, N. C. E. P. N. E. 2002. Third Report of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) final report. Circulation, 106, 3143. 
PANIDIS, D., TZIOMALOS, K., MACUT, D., KANDARAKI, E. A., TSOURDI, E. A., PAPADAKIS, E. 
& KATSIKIS, I. 2013. Age-and body mass index-related differences in the prevalence of metabolic 
syndrome in women with polycystic ovary syndrome. Gynecological Endocrinology, 29, 926-930. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
19 
 
RAHMANPOUR, H., JAMAL, L., MOUSAVINASAB, S. N., ESMAILZADEH, A. & AZARKHISH, K. 
2012. Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in 
adolescents. J Pediatr Adolesc Gynecol, 25, 208-12. 
ROSSI, B., SUKALICH, S., DROZ, J., GRIFFIN, A., COOK, S., BLUMKIN, A., GUZICK, D. S. & 
HOEGER, K. M. 2008. Prevalence of metabolic syndrome and related characteristics in obese 
adolescents with and without polycystic ovary syndrome. The Journal of Clinical Endocrinology & 
Metabolism, 93, 4780-4786. 
SARTOR, B. M. & DICKEY, R. P. 2005. Polycystic ovarian syndrome and the metabolic syndrome. Am J 
Med Sci, 330, 336-42. 
SILVEIRA, L., BUONANI, C., MONTEIRO, P., MELLO ANTUNES, B. & FREITAS JÚNIOR, I. 2013. 
Metabolic Syndrome: Criteria for Diagnosing in Children and Adolescents. Endocrinol Metab Synd, 
2, 2161-1017.100011. 
STEPTO, N. K., CASSAR, S., JOHAM, A. E., HUTCHISON, S. K., HARRISON, C. L., GOLDSTEIN, R. 
F. & TEEDE, H. J. 2013. Women with polycystic ovary syndrome have intrinsic insulin resistance 
on euglycaemic-hyperinsulaemic clamp. Hum Reprod, 28, 777-84. 
VRBIKOVA, J., ZAMRAZILOVA, H., SEDLACKOVA, B. & SNAJDEROVA, M. 2011. Metabolic 
syndrome in adolescents with polycystic ovary syndrome. Gynecol Endocrinol, 27, 820-2. 
VURAL, B., CALISKAN, E., TURKOZ, E., KILIC, T. & DEMIRCI, A. 2005. Evaluation of metabolic 
syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary 
syndrome. Human Reproduction, 20, 2409-2413. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
20 
 
Tables and figures 
 
 
Figure 1: Search strategy for Metabolic Syndrome in girls with PCOS 
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Figure 2: Meta-analysis of Systolic Blood Pressure 
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WMD: Weighted Mean difference, SBP: Systolic Blood Pressure, CI: Confidence interval 
 
 
Figure 3: Meta-analysis of Diastolic Blood Pressure 
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WMD: Weighted Mean difference, DBP: Diastolic Blood Pressure, CI: Confidence interval 
Figure 4: Meta-analysis of HDL levels 
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Figure 5: Meta-analysis of Triglycerides level 
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Figure 6: Meta-analysis of Glucose level 
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Figure 7: Meta-analysis of waist circumference 
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Figure 8: Meta-analysis of prevalence of Metabolic Syndrome 
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Figure 9: Funnel plot for meta-analysis of metabolic syndrome in girls with and without PCOS 
 
 
 
 
Figure 10: Funnel plot for meta-analysis of Systolic blood pressure 
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Figure 11: Funnel plot for meta-analysis of diastolic blood pressure 
 
Figure 12: Funnel plot for meta-analysis of triglycerides level 
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Figure 13: Funnel plot for meta-analysis of glucose level 
 
Figure 14: Funnel plot for meta-analysis of HDL level 
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Figure 15: Funnel plot for meta-analysis of waist circumference 
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Table 1: Definitions of polycystic ovarian syndrome for women according to NIH and Rotterdam/ESHRE 
criteria  
NIH (Carmina 2004) Rotterdam/ESHRE (Franks 2006) 
Both criteria: 
1. Chronic anovulation 
2. Clinical or biochemical 
hyperandrogenism 
Two or more of the following: 
1. Chronic Anovulation 
2. Clinical or biochemical 
hyperandrogenism 
3. Polycystic ovaries on ultrasound 
NIH: National Institute of Health, ESHRE: European Society of Human Reproduction and Embryology 
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Table 2: Definitions of metabolic syndrome according to Cook, de Ferranti et al, NCEP ATP lll and IDF 
criteria 
Cook et al. (2009) (paediatric criteria)  De Ferranti et al. (2004) (adolescent criteria)  
Three or more of the following: 
1. HDL : 40mg/dL or less 
2. BP : 90th percentile (age/sex/height) 
or more 
3. Glucose : 110mg/dL or more 
4. Waist circumference : 90th percentile 
(age/sex) or more 
5. Triglycerides : 110md/dL or more 
Three or more of the following: 
1. HDL < 50mg/dL 
2. BP : 90th percentile (age/sex/height) or 
more 
3. Glucose : 110mg/dL or more 
4. Waist circumference: 75th percentile 
(age/sex) or more 
5. Triglycerides : 100md/dL or more 
NCEP ATP lll (Panel, 2002)  IDF (adolescent criteria) (Alberti et al. 2007) 
 
Three or more of the following: 
1. WC : 88cm or more 
2. HDL< 1.3mmol/L (<50mg/dL) 
3. TG : 1.7 mmol/L (150mg/dL) or more 
4. BP : 135/85mmHg or more / on BP 
medication 
 
Central obesity (80cm or more) with two or 
more of the following: 
1. TG : 150mg/dL or more 
2. HDL : 1.9mmol/L (35mg/dL) 
3. BP : 130/85mmHg or more / on BP 
medication 
4. FBG : 5.6mmol/L (100md/dL) or more / 
previously diagnosed T2D 
 
BP = blood pressure, HDL = high density lipoprotein cholesterol, TG = triglycerides, WC = waist 
circumference, FBG = Fasting blood glucose 
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Table 3: Summary of studies assessing Metabolic Syndrome in women with and without PCOS 
Study ID PCOS Control Metabolic Syndrome 
definition 
Aydin et al 2015 
 
N = 63 ESHRE/ASRM  
Age = 10-19 
BMI<25kg/m2 
N = 159 
Age = 10-19 
BMI<25kg/m2 
Modified Cook 
criteria 
Bhattacharya et al 
2008 
 
N = 39 Rotterdam 
Age = 10-19 
 IDF criteria 
Fruzzetti et al 2009 
 
N = 53 
NIH/Rotterdam 
Age = 12-19 
N = 30 
Age = 12-19 
De Ferranti criteria 
Hart et al 2011 
 
N : 
Rotterdam = 61  
NIH = 34 
Age =  14-17 
N : 
Rotterdam = 143 
NIH = 169 
Age = 14-17 
EGIR, WHO, modified 
ATP, IDF, and 
the modified IDF  
Huang et al 2010 
 
N = 128 Rotterdam 
N = 90 NIH 
Age 17-19 
N = 40 
Age = 17-19 
IDF criteria 
Panidis et al 2013 
 
N = 332 Rotterdam 
Age = 18.1+_ 1.7 
N = 10 
Age 18.3+-1.1 
IDF 
Rahmanpour 2012 
 
N = 30 NIH 
Age = 14-18 
N = 71 
Age = 14-18 
IDF 
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Rossi et al 2008 
 
N = 43 Rotterdam 
Age = 12-18 
N = 31 
Age = 12-18 
IDF 
Vrbikova et al 2011 
 
N = 43 ESHRE 
Age= 16.8 
N = 48 
Age = 17.5 
IDF 
 
 
Table 4: Assessment of risk of bias in included studies using The Cochrane Collaboration’s tool (Higgins 
et al., 2011) 
 
Study ID Selection 
(Max 4 stars) 
Comparability 
(Max 2 stars) 
Exposure 
(Max 3 stars) 
Total 
(9 stars) 
Aydin et al 2015 ** * ** 5 
Bhattacharya et al 2008 **  * 3 
Fruzzetti et al 2009 *** * ** 6 
Hart et al 2011 **  * 3 
Huang et al 2010 *** ** *** 8 
Panidis et al 2013 **** ** ** 8 
Rahmanpour et al 2012 **** ** *** 9 
Rossi et al 2008 *** ** *** 8 
Vrbikova et al 2011 *** * ** 6 
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Table 5: Prevalence of the Metabolic Syndrome in subjects with PCOS 
 
Study ID MS prevalence in 
PCOS vs controls 
 
PCOS vs control for each 
outcome 
P value 
Aydin et al 
Observational 
Cross-sectional 
case-control 
study 
Cook: 7.9% vs 0.6% HDL : 61mg/dL vs 58mg/dL NS (p value not 
stated) 
BP :  
SBP ; 112.44 mm Hg vs 104.49 
mm Hg;    
DBP; 74.12 mmHg vs 69.01 mm 
Hg 
  
P<0.001  
 
P<0.007 
 
FG : 84mg/dL vs 86mg/dL NS 
Waist circumference : 77cm vs 
79cm 
NS 
Triglycerides : 91mg/dl vs 
79mg/dl 
 
P= 0.045 
Bhattacharya et 
al 
Medical record 
review 
 
 
IDF : 43.6%  
 
 
 
 
Central obesity with:  
 
 
 
 
TG : 0% 
HDL : 35% has low HDL level 
BP : elevated SBP : 47.1%, 
elevated DBP : 5.9%  
FBG : 11.8% has high FBG 
 
Fruzzeti et al 
Retrospective 
chart review 
 
 
 
 
 
 
 
De Ferranti : 9.4%   
(because of limited 
number of controls, 
the prevalence of 
MetS was not 
calculated) 
 
 
 
 
HDL :51 vs 57mg/dl P<0.05 
BP :  
SBP : 118mmHg vs 111mmHg 
DBP : 77mmHg vs 74mmHg 
 
P<0.05 
P = 0.29 
FG : 79.9mg/dL vs 79.3mg/dL 
 
P = 0.81 
Waist circumference: 79.5cm vs P = 0.15 
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75.6cm 
Triglycerides : 61mg/dl vs 47 
mg/dl 
 
P<0.01 
*Hart et al 
Prospective 
cohort study 
 
IDF  
Rotterdam : 4.9% 
vs 4.2% 
 
 
 
 
TG :  6.6% vs 5.6%  
 
 
BG : 3.3% vs 1.4% 
WC : 45.9% vs 29.4% 
HDL : 16.4% vs 7.7% 
BP : 3.3% vs 2.1% 
Huang et al 
Comparative 
Case control 
study 
4.7% (IDF), 6.7% 
(Rotterdam) vs 2.5 
% 
HDL : 1.6mmol/L,1.5mmol/L vs 
1.6mmol/L 
NS (p value not 
stated) 
BP : 110/71mmHg (both) vs 
100/62mmHg 
P<0.01 
TG : 1mmol/L (both) vs 
0.9mmol/L 
NS  
FBG : 4.8mmol/L (both) vs 
4.7mmol/L 
 
NS 
Panidis et al 
Comparative 
Case control 
study 
IDF: 30.1% vs 0% 
 
 
 
TG : 87.9mg/dl vs 80.3mg/dl NS (p value not 
stated) 
HDL : 38.9mg/dl vs 33mg/dl NS 
BP :  
SBP : 106.9 vs 95mmHg 
DBP : 68.6 vs 61mmHg 
 
P= 0.015 
P = 0.048 
Glucose : 97.4mg/dl vs 96.7mg/dl NS 
Rahmanpour et 
al 
Comparative 
Case control 
IDF : 33.3% vs 
11.26%  
 
 
TG : 108 vs 98.5mg/dl P = 0.045 
HDL : 35.5mg/dl vs 35.3mg/dl P = 0.94 
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study  
 
 
 BP :  
SBP : 108mmHg vs 103mmHg 
DBP 76.67 vs 70mmHg 
 
P = 0.059 
P = 0.02 
FBG : 96.6mg/dl 94.3mg/dl P = 0.56 
Rossi et al 
Cross-sectional 
case-control 
study 
IDF : 26% vs 19% 
 
TG : 90mg/dl vs 90mg/dl P = 0.98 
HDL : 39mg/dl vs 40mg/dl P = 0.44 
BP :   
SBP : 114mmHg vs 118mmHg 
DBP : 67mmHg vs 64mmHg 
 
P = 0.28 
P = 0.16 
FBG : 88mg/dl vs 87mg/dl P = 0.8 
Vrbikova et al 
Comparative 
Case control 
study 
IDF : 11% vs 2% 
 
 
 
TG : 0.98mmol/L vs 0.97mmol/L NS (p value not 
stated) 
HDL : 1.6 vs 1.3mmol/L P = 0.0007 
BP :  
SBP : 116mmHg vs 113mmHg 
DBP : 72mmHg vs 75.7mmHg 
 
NS 
NS 
BG : 4.79mmol/L vs 4.73mmol/L NS 
 
NS: not significant, TG : Triglycerides, HDL : high density lipoprotein cholesterol, LDL : low density 
lipoprotein cholesterol, SBP : systolic blood pressure, DBP : diastolic blood pressure, BP : blood pressure, 
FBG : Fasting blood glucose, WC : waist circumference.  
 
*Outcomes value was not reported in Hart et al. Only percentages of girls who have high metabolic 
parameters were calculated. 
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Table 6: Meta-analysis comparison between quality effects, random effects and Inverse Variance 
heterogeneity 
Components of Metabolic 
Syndrome (WMD ( 95% CI)) 
Quality Effects 
(QE) 
Random Effects 
(RE) 
Inverse Variance 
Heterogeneity (IVhet) 
Systolic Blood Pressure  5.00 (1.28, 8.72) 5.09 (1.41, 8.77) 5.31 (1.50, 9.12) 
Diastolic Blood Pressure 3.52 (0.48, 6.56) 3.32 (0.29, 6.35) 3.26 (0.11, 6.42) 
Tryglycerides level 4.23 (-3.39, 3.19)  6.71 (-0.41, 13.84) 2.99 (-7.01, 12.99) 
Glucose level 1.30 (-0.46, 3.05) 1.30 (-0.30, 2.90) 1.30 ( -0.30, 2.90) 
HDL level -1.43 (-4.85, 2.00) -1.13 (-4.41, 2.16) -1.99 (-5.51, 1.53) 
Waist circumference 5.28 4.09 5.00 
Metabolic Syndrome  
(OR (95% CI)) 
2.69 (1.29, 5.60) 2.73 (1.37, 5.45) 2.39 (1.18, 4.84) 
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